16 min
Season 2 - Episode 2: Regulatory Issues: What's Important Micro-dosing with Zeifmans: Short podcasts on demystifying the business of psychedelics
-
- Business
Join our host, Larry Zeifman and this week's guests, David Wood, PhD, Partner at BLG and Spencer Hawkswell, CEO of Therapsil - together they discuss CDSA exemptions, Therapsil's work within the psychedelics industry and the future of regulations for psychedelics as medication for mental health treatment.
About Zeifmans
Zeifmans is a full-service tax, accounting and consulting firm based in Toronto, Canada, ranked as one of Canada’s top 20 firms by revenue. Beyond the traditional offering, our services include business advisory, valuation, corporate finance, transaction services, corporate turnaround and insolvency, and estate and succession planning, supporting our 9,000+ clients through every step of the business life cycle. For more on our services relating directly to the cannabis and psychedelics industry, visit zeifmans.ca.
About Borden Ladner Gervais LLP (BLG):
As the largest, truly full-service Canadian law firm, Borden Ladner Gervais LLP (BLG) delivers practical legal advice for domestic and international clients across more practices and industries than any Canadian firm. With over 725 lawyers, intellectual property agents and other professionals, BLG serves the legal needs of businesses and institutions across Canada and beyond – from M&A and capital markets, to disputes, financing, and trademark & patent registration.
About TheraPsil
TheraPsil is a non-profit coalition dedicated to helping Canadians in medical need access legal, psilocybin-assisted psychotherapy to treat end-of-life distress. TheraPsil was formed in 2019 and is made up of healthcare professionals, patients, community members, and advocates. To meet our team, click here. After over 100 days of advocating, TheraPsil facilitated precedent-setting and tangible progress in the fight for compassionate access to psilocybin therapy when it helped 4 Canadians suffering from end-of-life distress, due to a terminal illness, access approved 'section 56 exemptions' from the Minister of Health, on August 4th 2020. This was the first time section 56 exemptions for psilocybin had been approved for patients since psilocybin was made a controlled substance in 1974, in Canada. As of March 2021, TheraPsil has now supported 27 patients in 5 different provinces access legal, psilocybin-assisted psychotherapy.
Join our host, Larry Zeifman and this week's guests, David Wood, PhD, Partner at BLG and Spencer Hawkswell, CEO of Therapsil - together they discuss CDSA exemptions, Therapsil's work within the psychedelics industry and the future of regulations for psychedelics as medication for mental health treatment.
About Zeifmans
Zeifmans is a full-service tax, accounting and consulting firm based in Toronto, Canada, ranked as one of Canada’s top 20 firms by revenue. Beyond the traditional offering, our services include business advisory, valuation, corporate finance, transaction services, corporate turnaround and insolvency, and estate and succession planning, supporting our 9,000+ clients through every step of the business life cycle. For more on our services relating directly to the cannabis and psychedelics industry, visit zeifmans.ca.
About Borden Ladner Gervais LLP (BLG):
As the largest, truly full-service Canadian law firm, Borden Ladner Gervais LLP (BLG) delivers practical legal advice for domestic and international clients across more practices and industries than any Canadian firm. With over 725 lawyers, intellectual property agents and other professionals, BLG serves the legal needs of businesses and institutions across Canada and beyond – from M&A and capital markets, to disputes, financing, and trademark & patent registration.
About TheraPsil
TheraPsil is a non-profit coalition dedicated to helping Canadians in medical need access legal, psilocybin-assisted psychotherapy to treat end-of-life distress. TheraPsil was formed in 2019 and is made up of healthcare professionals, patients, community members, and advocates. To meet our team, click here. After over 100 days of advocating, TheraPsil facilitated precedent-setting and tangible progress in the fight for compassionate access to psilocybin therapy when it helped 4 Canadians suffering from end-of-life distress, due to a terminal illness, access approved 'section 56 exemptions' from the Minister of Health, on August 4th 2020. This was the first time section 56 exemptions for psilocybin had been approved for patients since psilocybin was made a controlled substance in 1974, in Canada. As of March 2021, TheraPsil has now supported 27 patients in 5 different provinces access legal, psilocybin-assisted psychotherapy.
16 min